NASDAQ · Analyst Forecast

Pasithea Therapeutics Corp. (KTTA) Stock Forecast & Price Target

$0.43 NASDAQ: KTTA Market Cap $14.51M

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 17, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Pasithea Therapeutics Corp. (KTTA), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Pasithea Therapeutics Corp., analysts forecast revenue falling from $100,000 in 2022 to $0 in 2028; the average estimate for 2028 earnings per share is −$0.55; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$0.43
Consensus targetThe average of the price targets analysts have published.$3.00
Median targetThe middle target, less affected by a single outlier.$3.00
Highest targetThe most optimistic published target.$3.00
Lowest targetThe most pessimistic published target.$3.00
Difference from priceHow far the consensus target sits from today’s price.+597.7%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2022$100,000$100,000$100,0001
2023$500,000$500,000$500,0001
2025$0$0$01
2026$0$0$01
2027$0$0$01
2028$0$0$01

Earnings per share forecast

YearLowAverageHighAnalysts
2022−$7.00−$7.00−$7.001
2023−$10.80−$10.80−$10.801
2025−$1.50−$1.50−$1.501
2026−$0.76−$0.76−$0.761
2027−$0.46−$0.46−$0.461
2028−$0.55−$0.55−$0.551

Pasithea Therapeutics Corp. (KTTA) forecast — frequently asked questions

What is the analyst price target for Pasithea Therapeutics Corp.?

Analysts covering Pasithea Therapeutics Corp. (KTTA) have a consensus price target of $3.00, 597.7% above the current price of $0.43. Published targets range from $3.00 to $3.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Pasithea Therapeutics Corp.'s earnings?

The average analyst estimate for Pasithea Therapeutics Corp. (KTTA) earnings per share in 2028 is -0.55, with individual estimates between -0.55 and -0.55.

How much revenue is Pasithea Therapeutics Corp. expected to make?

Analysts forecast Pasithea Therapeutics Corp. (KTTA) revenue of $0 in 2028, based on 1 published estimates.

How many analysts cover KTTA?

1 analyst contribute estimates for Pasithea Therapeutics Corp. (KTTA). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.